Patients with well-defined conditions stemming from mTOR overactivation, such as tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM), present more suitable study subjects due to their targeted treatment needs and longer life expectancy. This evidence concerns the gene MTOR and tuberous sclerosis.